These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9565850)

  • 1. The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma.
    Simon A; Revel A; Hurwitz A; Laufer N
    J Assist Reprod Genet; 1998 Apr; 15(4):202-9. PubMed ID: 9565850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pathophysiology of ovarian hyperstimulation syndrome--views and ideas.
    Elchalal U; Schenker JG
    Hum Reprod; 1997 Jun; 12(6):1129-37. PubMed ID: 9221989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
    Rizk B; Aboulghar M; Smitz J; Ron-El R
    Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor.
    Pellicer A; Albert C; Mercader A; Bonilla-Musoles F; Remohí J; Simón C
    Fertil Steril; 1999 Mar; 71(3):482-9. PubMed ID: 10065786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome.
    Delvigne A; Rozenberg S
    Int J Fertil Womens Med; 2002; 47(5):211-26. PubMed ID: 12469708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome.
    Levin ER; Rosen GF; Cassidenti DL; Yee B; Meldrum D; Wisot A; Pedram A
    J Clin Invest; 1998 Dec; 102(11):1978-85. PubMed ID: 9835623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome.
    Kobayashi H; Okada Y; Asahina T; Gotoh J; Terao T
    J Mol Endocrinol; 1998 Jun; 20(3):363-74. PubMed ID: 9687159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian hyperstimulation syndrome: a new insight into an old enigma.
    Orvieto R; Ben-Rafael Z
    J Soc Gynecol Investig; 1998; 5(3):110-3. PubMed ID: 9614638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome.
    McClure N; Healy DL; Rogers PA; Sullivan J; Beaton L; Haning RV; Connolly DT; Robertson DM
    Lancet; 1994 Jul; 344(8917):235-6. PubMed ID: 7913160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ovarian Hyperstimulation Syndrome.
    Blumenfeld Z
    Vitam Horm; 2018; 107():423-451. PubMed ID: 29544639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
    Gómez R; Simón C; Remohí J; Pellicer A
    Endocrinology; 2002 Nov; 143(11):4339-48. PubMed ID: 12399430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.
    Abramov Y; Barak V; Nisman B; Schenker JG
    Fertil Steril; 1997 Feb; 67(2):261-5. PubMed ID: 9022600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum vascular endothelial growth factor levels before starting gonadotropin treatment in women who have developed moderate forms of ovarian hyperstimulation syndrome.
    D'Ambrogio G; Fasciani A; Monti M; Cattani R; Genazzani AR; Artini PG
    Gynecol Endocrinol; 1999 Oct; 13(5):311-5. PubMed ID: 10599547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ovarian hyperstimulation syndrome (OHS): borderlines between physiology and pathology].
    Piacentino R; Giobbe C; Giannotta MR; Porpiglia M; Minì D; Grio R
    Minerva Ginecol; 1994; 46(7-8):413-6. PubMed ID: 7970077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights in mechanisms for development of ovarian hyperstimulation syndrome.
    Kasum M
    Coll Antropol; 2010 Sep; 34(3):1139-43. PubMed ID: 20977119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiopathology of the renin-angiotensin system in the ovary.
    De Nuccio I; Salvati G; Genovesi G; Paolini P; Marcellini L; Schiavello V; Re M
    Minerva Endocrinol; 1999 Jun; 24(2):77-81. PubMed ID: 10941427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome.
    Albert C; Garrido N; Mercader A; Rao CV; Remohí J; Simón C; Pellicer A
    Mol Hum Reprod; 2002 May; 8(5):409-18. PubMed ID: 11994537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin system activation during severe OHSS: cause or effect?
    Manno M; Tomei F
    Fertil Steril; 2008 Feb; 89(2):488. PubMed ID: 18275884
    [No Abstract]   [Full Text] [Related]  

  • 20. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report.
    Krasnow JS; Berga SL; Guzick DS; Zeleznik AJ; Yeo KT
    Fertil Steril; 1996 Mar; 65(3):552-5. PubMed ID: 8774285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.